# A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )

> **NCT01227551** · PHASE2 · COMPLETED · sponsor: **Viralytics** · enrollment: 57 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** Coxsackievirus A21 (CVA21)

## Key facts

- **NCT ID:** NCT01227551
- **Lead sponsor:** Viralytics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-29
- **Primary completion:** 2016-04-06
- **Final completion:** 2016-04-06
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01227551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01227551, "A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM )". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01227551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*